11:07:25 Europe / Stockholm

Prenumeration

2023-08-21 13:40:00

In August, the Lenvima arm of the phase II study of fostrox in advanced liver cancer was fully recruited. Positive signals are emerging from readouts of the first ten patients. The first readout from all 15 patients will be published within a few months, which will be a major catalyst for the company.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/